**Core tip:** The results of our study show a moderately decreased platelet aggregation but no substantial impairment of the maximum clot firmness considering thrombelastometric results. Correlation analysis indicated that impedance aggregometric and thrombelastometric results did not correlate with model for end-stage liver disease score. Our data indicate that a potential coagulopathy in advanced liver cirrhosis may not be reflected by thrombelastometry or multiple electrode aggregometry as the underlying mechanisms may be beyond the platelet function of hemostasis. Rather, an individual assessment of a potential coagulopathy in patients with advanced disease is reasonable.

INTRODUCTION
============

Liver cirrhosis is the end stage for a variety of hepatic diseases\[[@B1]\] and leads to hemostatic alterations with distinct abnormalities of coagulation\[[@B2]\]. Changes in both conventional coagulation analysis and platelet count are common manifestations of decreased synthesis of coagulation factors and reduced platelet count in these patients. Despite laboratory findings suggesting a coagulopathy, fewer bleeding events in cirrhosis patients occur not as often as expected\[[@B3]\]. In recent years, there is increasing evidence that the observed changes in both coagulation factors and platelet count in patients with liver cirrhosis cannot be interpreted as a reliable indicator of a diffuse bleeding risk\[[@B4],[@B5]\]. The increasing knowledge on changes in hemostasis has meanwhile led to the concept of a rebalanced coagulation system\[[@B6]\]. However, a shift in hemostasis towards hypo- or hypercoagulation may occur in more advanced stages of liver failure. Routine diagnostic tests display relevant limitations, as they may not provide accurate information on the hemostatic status; they cannot predict bleeding risk and may therefore not provide clinically relevant information\[[@B7],[@B8]\].

Viscoelastic tests are global tests of coagulation, that assess the viscoelastic properties of noncentrifuged whole blood. As standard coagulation tests cannot predict the risk of bleeding\[[@B9]\], viscoelastic tests are already widely used for haemostatic management during liver transplantation (LT)\[[@B10]\] resulting in a reduced need for transfusion\[[@B11],[@B12]\]. Balancing the primary hemostasis is challenging and the underlying mechanisms that impair the primary hemostatic system are not completely understood\[[@B13]\].

A there is a lack of a universal platelet function assay in cirrhotic patients to assess bleeding risk or thrombotic events\[[@B14],[@B15]\], Only limited and inconsistent data are available for the application of platelet function testing in patients suffering from liver cirrhosis\[[@B16]-[@B18]\]. Therefore, the aim of the present study was to assess the haemostatic profile of patients suffering from mild to advanced liver cirrhosis, including platelet function testing using multiple electrode aggregometry (MEA; Multiplate^®^) and viscoelastic testing using thrombelastometry (ROTEM^®^) and furthermore to correlate results from both tests with the severity of liver cirrhosis.

MATERIALS AND METHODS
=====================

Study design and selection of patients
--------------------------------------

All patients attending the in- and outpatient care of the department of hepatology between December 2017 and May 2018 meeting the inclusion criteria were offered to participate in the present study. Inclusion criteria were liver cirrhosis and age of ≥ 18 years. Furthermore, a platelet count of at least 70 × 10^3^/µL was mandatory to ensure adequate measurement of MEA using the Multiplate analyzer. Patients were excluded when given a platelet concentrate three weeks prior to inclusion or in case of pregnancy.

Written informed consent was obtained from all patients. The study was performed in accordance with the Declaration of Helsinki. Approval of the local ethics committee was obtained before study was performed (reference \#195/17) and the study was registered to the Clinical Trials.gov Protocol Registration and Results System (NCT04265508). Patient care and study conduct complied with good clinical practice.

Demographic and biochemical data as well as medical history including cause of liver cirrhosis, end stage kidney failure, other diseases and medication with anticoagulants were recorded. Patients were included when having a model for end-stage liver disease (MELD) score of 6-11 or ≥ 17 and were stratified according to MELD score\[[@B19]\].

Laboratory analyses
-------------------

Venous blood was collected *via* a cannula inserted into a cubital vein. Collection tubes for conventional coagulation analysis were prefilled with sodium-citrate \[S-Monovette^®^ 1.8 mL, sodium-citrate 3.2% (1:10), Sarstedt AG, Nürnbrecht, Germany\] and analyzed by ACL Top 700 CTS (Werfen GmbH, Barcelona, Spain). Hematological analyses were performed using collection tubes prefilled with ethylene-diaminetetraacetate (S-Monovette^®^ 1.6 mL, K3 EDTA, Sarstedt AG Nürnbrecht, Germany) and analyzed by XN 9000 (Sysmex GmbH, Norderstedt, Germany). Platelet count was determined by fluorescence flow cytometry on XE 2100 (Sysmex GmbH, Norderstedt, Germany) and biochemical parameters were assessed using serum collection tubes (S-Monovette^®^ 7.5 mL, Serum Gel with clotting activator, Sarstedt AG, Nürnbrecht, Germany) and analyzed by Cobas 8000 (Roche diagnostics, Mannheim, Germany).

For ROTEM analysis, blood was collected in collection tubes prefilled with sodium-citrate \[S-Monovette^®^ 1.8 mL, citrate 3.2% (1:10), Sarstedt AG, Nürnbrecht, Germany\]. For MEA analysis, a heparinized blood gas analysis sample tube (safePICO, Radiometer, Krefeld, Germany) was used.

MEA
---

Platelet function was measured by MEA using the Multiplate analyzer 15min after blood draw and after activation with commercially available standard reagents (Roche, Basel, Swiss) as previously published\[[@B20]\]. Blood samples were analyzed at 37 °C. To test different ways of induction of aggregation, aggregation was stimulated (1) *via* adenosine diphosphate (ADP) receptors by ADP (ADP-test); (2) *via* arachidonic acid, the substrate of cyclooxygenase (COX), which subsequently forms the potent platelet activator thromboxane A~2~ (TXA~2~) (ASPI-test); and (3) by platelet receptor activating peptide 6 (TRAP-6) *via* the platelet surface platelet receptor (TRAP-test) as described in detail before\[[@B20]\]. To identify abnormal values in MEA assays, reference ranges were defined in accordance to the manufacturer's recommendations for heparinized blood samples\[[@B21]\].

Thrombelastometry
-----------------

Thrombelastometric assays were performed 15 min after blood draw. Blood samples were analyzed at 37 °C using ROTEM delta analyzer. Detailed description of the ROTEM analysis was already illustrated earlier\[[@B22]\]. A runtime of 60 min was applied and regular quality control tests and ROTEM tests (Werfen GmbH, Barcelona, Spain) were run in accordance with the manufacturer's instructions. For the present study, three tests were carried out using reagents provided by the manufacturer: Tissue factor triggered extrinsic pathway (EXTEM), which evaluates the extrinsic pathway; ellagic acid activated intrinsic pathway (INTEM), which evaluates the intrinsic pathway; cytochalasin D, which is an inhibitor of the rearrangement of microtubules in platelets and thus of platelet aggregation which evaluates the contribution of fibrinogen to clot formation (FIBTEM). To identify abnormal values in throm-belastometric assays, reference ranges were defined in accordance to previously published recommendations\[[@B23]\].

Statistical analysis
--------------------

A sample size estimation expecting a median difference of AUC~TRAP~ of ± 25% between the two groups was performed with α = 5% and power at 80% resulting in a computed sample size of *n* = 25 per group.

Data were tested for normality using Kolmogorov-Smirnov test. Data comparisons of patient characteristics and results of MEA and thrombelastometry were made using Mann-Whitney *U*- or Fisher's *exact*-test, where applicable. To correlate parameters from MEA and thrombelastometry with other parameters, Spearman rank correlation analysis fitting a linear regression line were performed.

Results with *P* \< 0.05 were considered to be statistically significant. All calculations/analyses were performed with SPSS (Version 25, Chicago, IL, United States) or GraphPad Prism (Version 8, San Diego, CA, United States).

The statistical methods of this study were reviewed by Prof. Eva Herrmann from the Department of Biostatistics and mathematical modeling of University Hospital Frankfurt.

RESULTS
=======

Patient characteristics
-----------------------

Between December 2017 and May 2018, a total of 67 patients suffering from liver cirrhosis attending the in- and out-patient care of the department of internal medicine were screened for inclusion into the study. Of these, 17 patients were not eligible to participate in the study: 8 patients presented with a platelet count lower than 70 × 10^3^/µL at the day of inclusion; further, 9 patients, who had a calculated MELD score of 12-16 were excluded, in order to create more distinct subgroups according to previously published data and study protocol\[[@B19]\] (Figure [1](#F1){ref-type="fig"}). In total, 50 patients were included for analysis: Cirrhosis resulted from nutritive toxic origin in 24 patients (48%), from hepatitis C in 9 patients (18%), from non-alcoholic steatohepatitis (NASH) in 6 patients (12%), from hepatitis B in 4 patients (8%) and of other origin in 7 patients (14%). Of these, 7 patients (14%) were placed on the liver transplant waiting list (Table [1](#T1){ref-type="table"}). Of the included patients, 25 suffered from mild liver cirrhosis according to a MELD score of 6 to 11, while the remaining 25 were included into advanced liver cirrhosis group presenting with a MELD score of 17 or above. Baseline patient characteristics revealed significant differences for MELD score and underlying laboratory parameters (international normalized ratio, bilirubin, creatinine) and for the level of fibrinogen an aPTT (Table [1](#T1){ref-type="table"}).

###### 

Patient characteristics

                                                **MELD 6-11 (*n* = 25)**   **MELD ≥ 17 (*n* = 25)**   ***P* value**
  --------------------------------------------- -------------------------- -------------------------- ---------------
  Age, yr (IQR)                                 62 (56-69)                 58 (56-66)                 0.58
  Male sex, *n* (%)                             12 (48)                    16 (64)                    0.39
  BMI (SD)                                      26 (6)                     27 (6)                     0.43
  MELD score (IQR)                              8 (7-10)                   22 (19-24)                 \< 0.0001
  Primary disease, *n* (%)                                                                            0.20
  NASH                                          2 (8)                      4 (16)                     
  Nutritive toxic                               15 (60)                    9 (36)                     
  Hepatitis B                                   2 (8)                      2 (8)                      
  Hepatitis C                                   5 (20)                     4 (16)                     
  Other                                         1 (4)                      6 (24)                     
  Listed for LT, *n* (%)                        2 (8)                      5 (20)                     0.41
  Renal replacement therapy, *n* (%)            0 (0)                      2 (8)                      0.49
  Anticoagulants, *n* (%)                       9 (36)                     11 (44)                    0.77
  P2Y12--receptor inhibitor                     1 (4)                      0 (0)                      
  ASA                                           5 (20)                     8 (32)                     
  LMWH                                          3 (12)                     3 (12)                     
  Laboratory parameters                                                                               
  Bilirubin, mg/dL (SD)                         0.9 (0.5)                  5.7 (4.4)                  \< 0.0001
  Creatinine, mg/dL (SD)                        0.8 (0.19)                 1.9 (1.5)                  \< 0.0001
  Urea, mg/dL (SD)                              28.7 (9.6)                 58.8 (41.6)                \< 0.001
  INR                                           1.1 (0.1)                  1.7 (0.6)                  \< 0.0001
  aPTT, s (SD)                                  30 (3.7)                   35 (7.5)                   0.047
  Fibrinogen, mg/dL (SD)                        275 (51)                   209 (90)                   0.006
  Platelet count, 10^3^/µL (SD)                 145 (51)                   138 (49)                   0.60
  Minimum, 10^3^/µL                             80                         72                         
  Maximum, 10^3^/µL                             275                        274                        
  Thrombocytopenia \< 150 × 10^3^/µL, *n* (%)   16 (64)                    18 (72)                    1.00

Data are given as means except for age which is presented as the median. Data comparisons were made with Mann Whitney *U* test or *χ*^2^ test where applicable. BMI: Body mass index; MELD: Model for end-stage liver disease; NASH: Nonalcoholic steatohepatitis; INR: International normalized ratio; aPTT: Activated partial thromboplastin time; ASA: Acetylsalicylic acid; LMWH: Low-molecular-weight heparin; LT: Liver transplantation; IQR: Indicates interquartile range.

![Detailed information on the patients that were included for analysis.](WJG-26-2097-g001){#F1}

MEA
---

Comparing medians of the results from MEA, no significant differences were detected between the mild or advanced liver cirrhosis group (Table [2](#T2){ref-type="table"}, Figure [2A](#F2){ref-type="fig"}). The overall median value of the ADP-test was 43 U (Table [2](#T2){ref-type="table"}). One patient on clopidogrel therapy was excluded from analysis in the advanced liver cirrhosis group. No significant difference between mild and advanced liver cirrhosis patients (*P* = 0.80) was observed in regard to incidence of platelet dysfunction, as defined by AUC~ADP~ below 55 U (Figure [2A](#F2){ref-type="fig"}).

###### 

Results of impedance aggregometric and thrombelastometric assays

                                                               **All patients**   **MELD 6-11**   **MELD ≥ 17**   ***P* value**
  ------------------------------------------------------------ ------------------ --------------- --------------- ----------------------------------
  Impedance aggregometry                                                                                          
  AUC~ADP~[1](#T2FN1){ref-type="table-fn"}, U (IQR)            43 (30-56)         45 (30-56)      42 (29-67)      0.80
  AUC~ADP~[1](#T2FN1){ref-type="table-fn"}\< 55 U, *n* (%)     34 (68)            17 (68)         17 (68)         0.58
  AUC ~ASPI~[2](#T2FN2){ref-type="table-fn"}, U (IQR)          71 (57-99)         72 (57-96)      68 (43-104)     0.53
  AUC~ASPI~[2](#T2FN2){ref-type="table-fn"} \< 79 U, *n* (%)   22 (44)            12 (48)         10 (40)         0.94
  AUC~TRAP~, U (IQR)                                           92 (61-106)        94 (80-109)     79 (60-110)     0.26
  AUC~TRAP~ \< 92 U, *n* (%)                                   24 (48)            9 (36)          15 (60)         0.09
  Thrombelastometry                                                                                               
  EXTEM                                                                                                           
  CT, s (IQR)                                                  71 (65-79)         70 (65-77)      73 (64-81)      0.52
  CT \< 42 s, *n* (%)                                          1 (2)              0               1 (4)           0.10
  CT \> 74 s, *n* (%)                                          19 (38)            8 (32)          11 (44)         0.38
  CFT, s (IQR)                                                 100 (75-115)       103 (82-109)    97 (67-132)     0.96
  CFT \< 46 s, *n* (%)                                         1 (2)              0 (0)           1 (4)           0.10
  CFT \> 148 s, *n* (%)                                        6 (12)             1 (4)           5 (20)          0.18
  MCF, mm (IQR)                                                57 (51-63)         58 (53-63)      52 (46-63)      0.06
  MCF \<49mm, *n* (%)                                          10 (20)            0 (0)           10 (40)         \< 0.001
  MCF \>71mm, *n* (%)                                          4 (8)              2 (8)           2 (8)           1.00
  α-angle, ° (IQR)                                             73 (69-77)         74 (70-76)      71 (66-80)      0.31
  α-angle \< 63°, *n* (%)                                      3 (6)              0 (0)           3 (12)          0.23
  α-angle \> 81°, *n* (%)                                      4 (8)              1 (4)           3 (12)          0.60
  INTEM                                                                                                           
  CT, s (IQR)                                                  197 (183-226)      195 (181-217)   202 (185-230)   0.80
  CT \< 137 s, *n* (%)                                         0 (0)              0 (0)           0 (0)           [a](#T2FN3){ref-type="table-fn"}
  CT \> 246 s, *n* (%)                                         9 (18)             4 (16)          4 (16)          1.00
  CFT, s (IQR)                                                 92 (69-110)        91 (80-109)     91 (62-120)     0.55
  CFT \< 40 s, *n* (%)                                         1 (2)              0 (0)           1 (4)           1.00
  CFT \> 100 s, *n* (%)                                        22 (44)            8 (32)          11 (44)         0.56
  MCF, mm (IQR)                                                54 (48-59)         55 (51-59)      52 (42-59)      0.16
  MCF \< 52 mm, *n* (%)                                        20 (40)            8 (32)          11 (44)         0.38
  MCF \> 72 mm, *n* (%)                                        1 (2)              0 (0)           1 (4)           1.00
  α-angle, °(IQR)                                              73 (69-76)         71 (67-75)      74 (69-80)      0.55
  α-angle \< 71°, *n* (%)                                      19 (38)            10 (40)         9 (36)          0.77
  α-angle \> 82°, *n* (%)                                      0 (0)              0 (0)           0 (0)           [a](#T2FN3){ref-type="table-fn"}
  FIBTEM                                                                                                          
  CT, s (IQR)                                                  63 (56-71)         59 (55-65)      68 (59-79)      0.004
  CT \< 43 s, *n* (%)                                          0 (0)              0 (0)           0 (0)           [a](#T2FN3){ref-type="table-fn"}
  CT \> 69 s, *n* (%)                                          3 (6)              4 (16)          9 (36)          0.19
  MCF, mm (IQR)                                                17 (12-20)         17 (14-20)      12 (9-21)       0.11
  MCF \< 9 mm, *n* (%)                                         4 (8)              0 (0)           4 (16)          0.11
  MCF \> 25 mm, *n* (%)                                        3 (6)              0 (0)           3 (12)          0.23

Data are presented as the median, with 25^th^-75^th^ percentiles shown within parentheses or count and percentage as indicated. Data comparisons were made with Mann-Whitney *U* test or *χ*^2^ test where applicable. Reference ranges of impedance aggregometric tests for area under the curve (AUC, U) were: AUC~ADP~: 55-117, AUC~ASPI~: 79-141. AUC~TRAP~: 92-151\[[@B23]\].

One patient on clopidogrel therapy was excluded from analysis;

13 patients on therapy with acetylsalicylic acid were excluded from analysis. *P* values are given for comparison between MELD 6-11 and MELD ≥ 17 groups.

No statistics were computed because no measured values were within the given range. AUC: Area under the curve; ADP: Adenosine-5 diphosphate; ASPI: Arachidonic acid; TRAP: Thrombin receptor activator peptide 6; MEA: Multiple electrode aggregometry; IQR: Indicates interquartile range; CT: Clotting time; CFT: Clot formation time, MCF: Maximum clot firmness.

![Impedance aggregometry and thrombelastometry in patients with mild and severe liver cirrhosis. A: Box and whisker plots of impedance aggregometry: Results are presented for area under the curve (AUC) of ADP (a), AUC~ASPI~ (b) and AUC~TRAP~ (c); B: Box and whisker plots of thrombelastometry: Presented are results of EXTEM clotting time (CT) (a), EXTEM clot formation time (b), EXTEM maximum clot firmness (MCF) (c), EXTEM α-angle (d), INTEM CT (e), INTEM clot formation time (f), INTEM MCF (g), INTEM α-angle (h), FIBTEM CT (i) and FIBTEM MCF (j). The lower and upper bars represent the minimum and maximum, respectively. The lower and upper ends of the box represent the 25^th^ and 75^th^ percentiles, respectively; the line in the box represents the median. Data comparisons were made using Mann-Whitney *U*-test. ADP: Adenosine-5 diphosphate; ASPI: Arachidonic acid; TRAP: Thrombin receptor activator peptide 6; MELD: Model for end-stage liver disease; CT: Clotting time; CFT: Clot formation time; MCF: Maximum clot firmness.](WJG-26-2097-g002){#F2}

The overall median of the ASPI-test was 71 U (Table [2](#T2){ref-type="table"}). To avoid a distortion of the results of the ASPI-test, 5 patients of the MELD 6-11 and 8 of the MELD ≥ 17 group with known acetylsalicylic acid intake were excluded from analysis. Comparing presence of platelet dysfunction, as defined by AUC~ASPI~ \< 79 U, there was no significant difference between patients with mild or advanced liver cirrhosis (Table [2](#T2){ref-type="table"}, Figure [2A](#F2){ref-type="fig"}).

The overall median of the TRAP-test was 92 U (Table [2](#T2){ref-type="table"}). Platelet dysfunction defined as AUC~TRAP~ below 92 U was detected in 9 (MELD 6-11) and 15 (MELD ≥ 17) patients, respectively, without any statistical significance between the groups (Figure [2A](#F2){ref-type="fig"}).

Thrombelastometry
-----------------

The overall median values of thrombelastometric analyses were within the normal reference ranges (Table [2](#T2){ref-type="table"}). Comparing medians of clotting time (CT), clot formation time (CFT), maximum clot firmness (MCF) and α-angle of EXTEM assay, no statistical differences between mild and advanced liver cirrhosis group were detected (Figure [2B](#F2){ref-type="fig"}). Also, no statistically significant differences were observed regarding median values of CT, CFT, MCF and α-angle of INTEM assay (Figure [2B](#F2){ref-type="fig"}). Regarding FIBTEM assay, median CT differed significantly in comparison between mild and advanced liver cirrhosis group (59 *vs* 68, *P* = 0.004) (Table [2](#T2){ref-type="table"}, Figure [2B](#F2){ref-type="fig"}). Comparing the frequency of pathological results of thrombelastometry, a significantly higher number of patients with reduced MCF~EXTEM~ was observed in the advanced liver cirrhosis group (0 *vs* 10, *P* \< 0.001) (Table [2](#T2){ref-type="table"}).

Correlation of MEA
------------------

We performed a Spearman rank correlation analysis and fitted a linear regression line for platelet count and results of MEA. AUC~TRAP~ (*P* = 0.30, *R*^2^ = 0.005) and AUC~ASPI~ (*P* = 0.46, *R*^2^ = 1.4e^-006^) revealed no significant correlation with platelet count. A significant correlation of AUC~ADP~ with platelet count was detected (*P* \< 0.0001, *R*^2^ = 0.21, Figure [3A-C](#F3){ref-type="fig"}). Spearman rank correlation analysis and fitting a linear regression line were also performed for MELD score and results of MEA. AUC~ADP~ (*P* = 0.45, *R*^2^ = 0.04), AUC~ASPI~, (*P* = 0.86, *R*^2^ = 0.003) and AUC~TRAP~ (*P* = 0.37, *R*^2^ = 0.02) revealed no significant correlation with MELD score (Figure [3D-F](#F3){ref-type="fig"}).

![Spearman rank correlation analysis and linear regression line fitting of area under the curve of impedance aggregometric assays. A-C: Scatterplots illustrating the relationship between platelet count and area under the curve (AUC, U) of impedance aggregometric assay: ADP-test (A), ASPI-test (B), TRAP-test (C); D-F: Scatterplots illustrating the relationship between model for end-stage liver disease score and AUC (U) of impedance aggregometric assay: ADP-test (D), ASPI-test (E), TRAP-test (F). Spearman rank correlation coefficients (*R*^2^) between model for end-stage liver disease score and AUC of impedance aggregometry with *P* values are given for each test. The upper and lower reference ranges of AUC are highlighted in the grey area. AUC: Area under the curve; ADP: Adenosine-5 diphosphate; ASPI: Arachidonic acid; TRAP: Thrombin receptor activator peptide 6; MELD: Model for end-stage liver disease.](WJG-26-2097-g003){#F3}

Correlation of thrombelastometry
--------------------------------

Spearman rank correlation analysis and fitting a linear regression line were also performed for MELD score and results of thrombelastometry. CT of EXTEM (*P* = 0.43, *R*^2^ = 0.002), INTEM (*P* = 0.85, *R*^2^ = 0.001) as well as CFT of EXTEM (*P* = 0.88, *R*^2^ = 0.001) and INTEM (*P* = 0.39, *R*^2^ = 0.004) revealed no significant correlation with MELD score (Figure [4](#F4){ref-type="fig"}). CT of FIBTEM (*P* = 0.02, *R*^2^ = 0.21) was significantly correlated to MELD score, demonstrating an increasing CT~FIBTEM~ corresponding to an increasing MELD score (*P* = 0.02, *R*^2^ = 0.21, Figure [4](#F4){ref-type="fig"}).

![Spearman rank correlation analysis and linear regression line fitting between model for end-stage liver disease score and results of thrombelastometry. Scatterplots illustrating the relationship between model for end-stage liver disease score and results of thrombelastometry: A: EXTEM clotting time (CT); B: EXTEM maximum clot firmness (MCF); C: EXTEM clot formation time; D: ECTEM α-angle; E: INTEM CT; F: INTEM MCF; G: INTEM clot formation time; H: INTEM α-angle; I: FIBTEM CT; and J: FIBTEM MCF. Spearman rank correlation coefficients squared (*R*^2^) between model for end-stage liver disease score and AUC of impedance aggregometry and linear regression with *P* values are given for each test. The upper and lower reference ranges of area under the curve are highlighted in the grey area. CT: Clotting time; CFT: Clot formation time; MCF: Maximum clot firmness; MELD: Model for end-stage liver disease.](WJG-26-2097-g004){#F4}

In correlation analyses of MCF of EXTEM (*P* = 0.08, *R*^2^ = 0.04), INTEM (*P* = 0.38, *R*^2^ = 0.01) and FIBTEM (*P* = 0.09, *R*^2^ = 0.04) no significant correlations to MELD score were observed. α-angle of EXTEM (*P* = 0.58, *R*^2^ = 0.003) and INTEM (*P* = 0.20, *R*^2^ = 0.03) did not correlate significantly with MELD score (Figure [4](#F4){ref-type="fig"}).

Analysis of MCF of EXTEM (*P* \< 0.0001, *R*^2^ = 0.45), INTEM (*P* \< 0.0001, *R*^2^ = 0.44) and FIBTEM (*P* = 0.03, *R*^2^ = 0.09) showed significant correlations with platelet count (Supplementary Figure 1). Moreover, analysis of MCF of EXTEM (*P* \< 0.0001, *R*^2^ = 0.35), INTEM (*P* \< 0.0001, *R*^2^ = 0.31) and FIBTEM (*P* \< 0.0001, *R*^2^ = 0.63) demonstrated significant correlations with fibrinogen level (Supplementary Figure 2).

DISCUSSION
==========

Our prospective study in 50 patients with suffering from mild to advanced liver cirrhosis showed that the hemostatic profile assessed by MEA and thrombe-lastometric assays is not associated with the severity of liver cirrhosis according to MELD Score and ranged from normal to hypocoagulable state.

While most studies evaluating platelet function in liver cirrhosis are focused on LT, the aim of the present work was to conduct an analysis of platelet function in patients with liver cirrhosis in daily routine beyond surgery and to use MEA as the testing method. Our findings of MEA tests showed that platelet function was within or scarcely below the lower reference range for all performed tests. As a consequence, it appears to be inappropriate to universally label these patients as being pathologic concerning primary hemostasis.

In detail, comparing the observed MEA results to severity of liver cirrhosis, those patients who displayed abnormal results below the reference range showed mostly mild thrombopenia especially in the group of advanced liver cirrhosis. Thrombopenia in liver cirrhosis is well described and known to occur in affected patients\[[@B3],[@B24]\]. However, a long-accepted association with thrombocytopathia in thrombopenic cirrhosis patients, has been increasingly questioned by various publications\[[@B6],[@B15],[@B17],[@B25]\]. The mentioned publications provide evidence, that a consistent and predictable impairment in hemostasis may not be universal in patients with cirrhosis. Rather seems to be the coagulation status in a fragile but delicate balance between pro- and anticoagulation in cirrhosis patients\[[@B3],[@B12]\]. Further supporting these findings, data from clinical trials showed a lack of association between thrombopenic cirrhotic patients and bleeding events\[[@B26],[@B27]\].

Concerning platelet activation and aggregability, our findings show a slight to moderate impairment of platelet function in liver cirrhosis patients. Such decreased agonist-induced platelet aggregation has been demonstrated in previously published studies mainly by analyzing von-Willebrand factor (vWF) parameters\[[@B28],[@B29]\], by biochemical investigations\[[@B30],[@B31]\] or by using PFA-100\[[@B32],[@B33]\]. Despite these various approaches, the causes for platelet dysfunction in liver cirrhosis are complex and not fully clarified yet. Earlier studies suggested hypoaggregability as a result of impaired platelet activation, but recent research identified an oversecretion of P-selectin by platelets resulting from increased cyclooxygenase 1 activation as a potential cause for hypoaggregability\[[@B34]\]. Similar to the extent of thrombocytopenia and stage of liver cirrhosis\[[@B35]\], an increased activation of platelets could be associated to progression of cirrhosis, suggesting diminution of platelet count as a non-desired, but protective effect against intensification of inflammatory processes\[[@B36],[@B37]\]. Beyond that, an increased vWF level demonstrated for cirrhosis patients\[[@B38]\] might compensate for the quantitative platelet defect.

Considering all the above-mentioned alterations in platelet function of cirrhotic patients, a finely tuned balance seems to prevail, not only in plasmatic and cellular components, but also regarding for the platelet function.

However, a significant correlation of platelet dysfunction and platelet count was in contrast to results of non-cirrhotic patients\[[@B39]\] only detected for AUC~ADP~, which reinforces previous published data\[[@B16],[@B25]\] and highlights the alterations in primary hemostasis of these patients. This finding may be related to the higher sensitivity of the ADP-test in comparison to the thrombin-dependent tests as reported earlier in cardiac surgery patients\[[@B40]\].

Furthermore, ADP-, ASPI- and TRAP-tests were not significantly deteriorated in comparison of patients with mild and advanced liver cirrhosis, which may also be related to the mentioned compensating mechanisms of thrombocytopenia.

MEA records platelet aggregation in-vitro in response to given test reagents as mentioned above. The purpose of this method is to determine the platelet function in patients on antiaggregatory medication, as well as in the pre- and postoperative setting. Until today, only one other study showed results of measuring platelet function of liver cirrhotic patients used this approach\[[@B16]\]. It therefore remains unclear to what extent the alteration of *e.g*., hepatic TXA~2~ metabolism, over secretion of P-selectin, changes in thrombin generation and chronic inflammation might contribute to an impaired in-vitro platelet aggregation using MEA and further studies are required to assess MEA as an adequate tool in liver cirrhotic patients\[[@B15],[@B41]\]. Additional studies addressing the impact of pathological coagulation as per MEA testing on the development of clinically relevant bleeding events are necessary.

In line with the literature our results of EXTEM, INTEM and FIBTEM assays varied from normal to hypocoagulable status\[[@B42]\] without significant differences according to MELD score. Our results reinforce the assumptions on alterations in plasmatic coagulation of cirrhotic patients\[[@B43]\] and follow the concept of a balanced hemostatic coagulation status\[[@B6]\]. These are important findings, as clinical practice of platelet transfusion is occasionally based on reduced MCF~EXTEM~. In line with previously published data suggesting platelet transfusion in cases of reduced maximum clot firmness\[[@B44],[@B45]\], our findings again highlight the presumably specific hemostatic balance of these patients and support the current recommendations to avoid correction of pathological values as determined by conventional coagulation analysis. Since our results did not reveal correlation with the severity of liver cirrhosis - in contrast to previous published data\[[@B46]\] - the MELD score should not be used to assess hemostatic potential or to guide hemostatic therapy.

Study limitations
-----------------

To ensure adequate performance of MEA, patients suffering from severe thrombocytopenia were not included into the study. Hence, findings in MEA or thrombelastometry may differ in those severely affected patients. Moreover, results of MEA provide only restricted information of platelet function, which might not be adequate to assess platelet function in liver cirrhosis. Measuring platelet function using other point-of-care tests with different approaches would be an interesting aim in future studies. Transfer of the presented findings to patients suffering from other diseases should be done with caution due to the distinct alterations in the hemostatic profile of patients with liver cirrhosis.

In conclusion, our data demonstrate a partially impaired hemostatic profile of both platelet function and plasmatic coagulation in cirrhotic patients, but no correlation of impairment with the severity of liver cirrhosis. Therefore, the hemostatic potential or a hemostatic therapy should not be judged by MELD score alone but rather by an individual and patient-specific assessment.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

Liver cirrhosis leads to hemostatic alterations. Despite laboratory findings suggesting a coagulopathy, these do not reflect bleeding events in cirrhosis patients. Routine diagnostic tests display relevant limitations, as they may not provide accurate information on the hemostatic status; they cannot predict bleeding risk and may therefore not provide clinically relevant information.

Research motivation
-------------------

Viscoelastic tests are global tests of coagulation, which assess the viscoelastic properties of blood. The aim of the present study was to assess the haemostatic profile of patients suffering from mild to advanced liver cirrhosis, including platelet function testing and viscoelastic testing. Results originating from these tests may close the gap in testing patients with liver cirrhosis for

Research objectives
-------------------

The objective was to study the hemostatic profile of patients with liver cirrhosis and to correlate results from both tests with the severity of liver cirrhosis.

Research methods
----------------

Platelet function was measured by multiple electrode aggregometry using the multiplate analyzer 15 min after blood draw and after activation with commercially available standard reagents. Blood samples were analyzed at 37 °C. Thrombelastometric assays were performed 15 min after blood draw. Blood samples were analyzed at 37 °C using ROTEM delta analyzer. A runtime of 60 min was applied and regular quality control tests and ROTEM tests were run in accordance with the manufacturer's instructions. Data comparisons of patient characteristics and results of multiple electrode aggregometry (MEA) and thrombelastometry were made using Mann-Whitney *U*- or Fisher's *exact*-test, where applicable. To correlate parameters from MEA and thrombelastometry with other parameters, Spearman rank correlation analysis fitting a linear regression line were performed.

Research results
----------------

Our prospective study in 50 patients with suffering from mild to advanced liver cirrhosis showed that the hemostatic profile assessed by viscoelastic tests is not associated with the severity of liver cirrhosis according to model for end-stage liver disease (MELD) score and ranged from normal to hypocoagulable state. In detail, comparing the observed MEA results to severity of liver cirrhosis, those patients who displayed abnormal results below the reference range showed mostly mild thrombopenia especially in the group of advanced liver cirrhosis.

Research conclusions
--------------------

Our data demonstrate a partially impaired hemostatic profile of both platelet function and plasmatic coagulation in cirrhotic patients, but no correlation of impairment with the severity of liver cirrhosis. Therefore, the hemostatic potential or a hemostatic therapy should not be judged by MELD score alone but rather by an individual and patient-specific assessment. Further, our data indicate that a potential coagulopathy in advanced liver cirrhosis may not be reflected by thrombelastometry or multiple electrode aggregometry as the underlying mechanisms may be beyond the platelet function of hemostasis. In clinical practice, viscoelastic testing may prove to be an asset in the assessment of hemostatic profiling of patients suffering from liver cirrhosis.

Research perspectives
---------------------

Ultimately, further tests need to be developed to further reflect/identify patients with an impaired hemostatic potential.
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